Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Gut health drink may tame blood sugar in menopause

NCT ID NCT07565675

Disease control Sponsor: University of Roehampton Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a daily prebiotic drink (containing inulin) can improve blood sugar control in 30 postmenopausal women with prediabetes. Participants will consume the drink or a placebo for 4 weeks. The goal is to see if this simple dietary supplement can help reduce the risk of type 2 diabetes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
inulin (a prebiotic fiber)
What this could lead to
If it works, this could offer a simple, non-drug way to help postmenopausal women with prediabetes improve their blood sugar control.
What could go wrong
This is a very small, early-stage trial with only 30 participants and a short 4-week duration. Results may not be generalizable, and the effect on long-term diabetes prevention is unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

May 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

45 to 60 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria:: * Female, aged 45-60 years * Post-menopausal (no menstrual period for ≥12 months) * No serious long-term medical conditions * Living in the UK * Able to read English and provide electronic informed consent * Willing and able to comply with study procedures, including dietary intervention and sample collection * Willing to provide stool samples at specified time points * BMI ≥25 kg/m² with one of the following: * Impaired glucose tolerance (7.8-11.0 mmol/L at 2-hour OGTT), or * Impaired fasting glucose (5.6-6.9 mmol/L), or * HbA1c 5.7%-6.4% * No intentional dieting within the past month * No \>5% body weight loss in the past year * No changes in physical activity in the past 2-4 weeks and no intention to change during the study Exclusion Criteria: * Significant gastrointestinal disease (e.g., inflammatory bowel disease, coeliac disease) or other major medical conditions affecting gut microbiota or study safety * Immunocompromised status or other serious chronic illness * Use of antibiotics within the past 2-3 months * Regular use of probiotics or prebiotics within the past 4 weeks * Use of medications or special diets that significantly affect gut microbiota (e.g., chronic laxatives, immunosuppressants) * Known allergies or intolerances to components of the prebiotic formulation * Participation in another interventional clinical trial within the past 3 months

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Menopause are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diabetes mellitus Obesity prediabetes syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Menopause

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Health Sciences Research Centre, Life Sciences Department, University of Roehampton

    London, UK, SW15 4JD, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.